Wang, X., Wang, W., Cao, D., Hu, B., Zhang, S., Shen, B. (2026). An investigator-initiated phase I study evaluating the safety, tolerability, and preliminary efficacy of a personalized neoantigen mRNA vaccine (XP-004) combined with PD-1 inhibitor as adjuvant therapy in resected pancreatic cancer patients intolerant to chemotherapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2509